IXICO (IXI) Competitors GBX 11.76 -0.50 (-4.04%) As of 08/1/2025 04:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock IXI vs. FUM, SBTX, TRX, COS, C4XD, DDDD, SAR, OKYO, AREC, and AORShould you be buying IXICO stock or one of its competitors? The main competitors of IXICO include Futura Medical (FUM), SkinBioTherapeutics (SBTX), Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Sareum (SAR), OKYO Pharma (OKYO), Arecor Therapeutics (AREC), and AorTech International (AOR). These companies are all part of the "biotechnology" industry. IXICO vs. Its Competitors Futura Medical SkinBioTherapeutics Tissue Regenix Group Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Sareum OKYO Pharma Arecor Therapeutics AorTech International Futura Medical (LON:FUM) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Which has stronger valuation and earnings, FUM or IXI? IXICO has higher revenue and earnings than Futura Medical. Futura Medical is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFutura Medical£8.68M4.49-£3.88M-£1.21-10.31IXICO£11.50M0.95-£3.58M-£3.86-3.05 Is FUM or IXI more profitable? IXICO has a net margin of -31.10% compared to Futura Medical's net margin of -44.64%. IXICO's return on equity of -19.14% beat Futura Medical's return on equity.Company Net Margins Return on Equity Return on Assets Futura Medical-44.64% -56.44% -26.59% IXICO -31.10%-19.14%-10.40% Which has more risk & volatility, FUM or IXI? Futura Medical has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, IXICO has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Do insiders and institutionals have more ownership in FUM or IXI? 35.7% of Futura Medical shares are held by institutional investors. Comparatively, 56.0% of IXICO shares are held by institutional investors. 32.1% of Futura Medical shares are held by company insiders. Comparatively, 30.3% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to FUM or IXI? In the previous week, Futura Medical had 1 more articles in the media than IXICO. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for IXICO. Futura Medical's average media sentiment score of 1.11 beat IXICO's score of 0.00 indicating that Futura Medical is being referred to more favorably in the media. Company Overall Sentiment Futura Medical Positive IXICO Neutral SummaryIXICO beats Futura Medical on 7 of the 13 factors compared between the two stocks. Get IXICO News Delivered to You Automatically Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXI vs. The Competition Export to ExcelMetricIXICOBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£10.89M£134.51M£5.49B£3.03BDividend Yield1.27%3.74%4.73%5.02%P/E Ratio-3.053.8128.78176.75Price / Sales0.954,246.60372.20264,362.45Price / Cash2.2513.1935.4527.97Price / Book0.6039.388.274.53Net Income-£3.58M-£90.99M£3.25B£5.90B7 Day Performance4.72%-1.84%-3.70%12.58%1 Month Performance14.74%11.20%4.34%6.10%1 Year Performance67.93%189.79%25.90%71.60% IXICO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXIIXICON/AGBX 11.76-4.0%N/A+73.5%£10.89M£11.50M-3.0589Gap UpFUMFutura MedicalN/AGBX 13.05+0.8%N/A-65.3%£40.68M£8.68M-10.7712Positive NewsHigh Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 16.70-0.3%N/A+19.3%£38.15M£1.56M-10.2711TRXTissue Regenix GroupN/AGBX 39.52+1.3%N/A-47.7%£35.63M£31.98M-40.80120Gap UpCOSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106News CoverageSARSareumN/AGBX 18.90+5.0%N/A-43.5%£23.61MN/A-4.483,211OKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownARECArecor TherapeuticsN/AGBX 55+5.8%N/A-36.3%£20.77M£6.04M-1.9410News CoverageHigh Trading VolumeAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383 Related Companies and Tools Related Companies FUM Competitors SBTX Competitors TRX Competitors COS Competitors C4XD Competitors DDDD Competitors SAR Competitors OKYO Competitors AREC Competitors AOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:IXI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IXICO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share IXICO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
